 | Up a level |
Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Bahlo, J., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). A new prognostic model based on clinical, biological and genetic parameters improves prognostication in early stage CLL patients: results of the prospective CLL1 trial of the German CLL study group. Oncol. Res. Treat., 40. S. 25 - 27. BASEL: KARGER. ISSN 2296-5262
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Bahlo, J., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31 (12). S. 2833 - 2838. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551